UK cost agency turns down Bristol drug for head and neck cancer - Nasdaq

Nasdaq

UK cost agency turns down Bristol drug for head and neck cancer Nasdaq LONDON, April 11 (Reuters) - Britain's healthcare cost-effectiveness watchdog NICE said on Tuesday that Bristol-Myers Squibb's <BMY.N> immunotherapy drug Opdivo was not worth using on the state health service for treating head and neck cancer due to ... and more »

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oZKwAM
via IFTTT